在您下載用藥資訊前可以先閱讀「癌症用藥知識您不可不知」
癌症藥物(專業版)
所有分類
- ALK TKI
- Angiogenesis
- BcrABL TKI
- BRAF inhibitors
- BTK inhibitors TKI
- CDK inhibitors
- Conjugated antibody
- EGFR TKI
- FGFR2 inhibitors TKI
- Her2 inhibitors TKI
- KRAS inhibitors TKI
- MEK inhibitors TKI
- Monoclonal antibody
- mTOR inhibitors
- Multikinase inhibitors
- NTRK inhibitors TKI
- PARP inhibitors
- Phosphoinositide 3-kinase inhibitors
- Proteasome inhibitors
- Immune modulator
- BCL-2 inhibitor
- FLT3 inhibitors
- JAK inhibitors
- IL6 inhibitors
Entrectinib (Rozlytrek®) 羅思克®100mg / 200mg膠囊
Entrectinib(Rozlytrek®)羅思克®100mg/200mg膠囊作用機轉：口服標靶藥物，為TRK(tropomyosinreceptortyrosinekinases，TRKA、TRKB、TRKC)、ROS1、ALK抑制劑，亦可抑制JAK2與TNK2。多種腫瘤類型的癌細胞株含有TRK
Larotrectinib (VITRAKVI) 維泰凱 25/100 mg膠囊
Larotrectinib(VITRAKVI)維泰凱25/100mg膠囊作用機轉：口服標靶藥物，Larotrectinib是對3種原肌球蛋白受體激酶（TRK）蛋白TRKA，TRKB和TRKC有效且高度選擇性的小分子抑製劑。TRKA，TRKB和TRKC由神經營養性受體酪氨酸激酶（NTRK）的由NTRK
